# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 563 results.
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 16, 2020
First Received: Jun 16, 2020
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Copanlisib
Locations: Ospedale Monsignor Raffaele Dimiccoli - Ematologia, Barletta, Barletta-Andria-Trani, Italy
Istituto Clinico Humanitas - U.O. Ematologia, Rozzano, Milano, Italy
Centro Riferimento Oncologico - S.O.C. Oncologia Medica A, Aviano, Pordenone, Italy
IRCCS-Centro di Riferimento Oncologico - UO di Ematologia e Trapianto Cellule Staminali, Rionero In Vulture, Potenza, Italy
Ospedale Dell'Angelo - U.O. Ematologia, Mestre, Venezia, Italy
... and 25 other locations.
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 25, 2020
First Received: Mar 18, 2020
Disease(s): B-cell Lymphoma
Intervention(s): Glofitamab, Gemcitabine, Oxaliplatin, Mosunetuzumab, Obinutuzumab, Tocilizumab
Locations: Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
Monash Health Monash Medical Centre, Clayton, Victoria, Australia
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Status: Not yet recruiting
Last Changed: Jun 11, 2020
First Received: Nov 01, 2019
Disease(s): Non-Hodgkin's B-cell Lymphoma
Intervention(s): DZD9008
Locations: Jiangsu Province Hospital - Haematology, Nanjing, China
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Apr 01, 2020
First Received: Apr 11, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone, Dexamethasone, Thalidomide
Locations: Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: Mar 11, 2020
First Received: Aug 14, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Pembrolizumab
Locations: Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States
University of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States
University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
Novartis Investigative Site, Wien, Austria
... and 3 other locations.
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: May 12, 2020
First Received: May 12, 2020
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin
Multi-CAR-T Cells Targeting B Cell Lymphomas
Status: Recruiting
Last Changed: Jun 12, 2020
First Received: Jun 12, 2020
Disease(s): B Cell Lymphoma (BCL)
Intervention(s): 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
Locations: Shenzhen Children's Hospital, Shenzhen, Guangdong, China
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Status: Recruiting
Last Changed: Jan 21, 2020
First Received: Mar 15, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Tisagenlecleucel, Ibrutinib
Locations: Stanford University, Palo Alto, California, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Status: Recruiting
Last Changed: May 13, 2020
First Received: Oct 12, 2018
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Locations: Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/ Oncology, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 2 other locations.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 29, 2020
First Received: Jun 28, 2019
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Axicabtagene Ciloleucel, Rituximab, Lenalidomide, Fludarabine, Cyclophosphamide
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/Oncology, Santa Monica, California, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
... and 8 other locations.